Late Breaking News
Department of Defense (DoD)
SAN DIEGO - Low levels of vitamin D are associated with a higher risk of developing "insulin-requiring" diabetes, according to a study of active-duty servicemembers.
INDIANAPOLIS, IN - A new study from the Roudebush VAMC in Indianapolis suggests survival rates are better when diabetes patients with multivessel coronary artery disease receive coronary artery bypass graft (CABG) surgery as opposed to angioplasty, even when the most current drug-eluting stents (DES) are used.1
WASHINGTON - A new Army report suggests that doctors made changes to PTSD diagnoses during the Medical Evaluation Board (MEB) process at similar rates to other behavioral health diagnoses, “suggesting that PTSD is not handled differently than other diagnoses.”
WEST POINT, NY - Young military cadets undergoing an allograft ACL reconstruction were significantly more likely to experience clinical failure requiring revision reconstruction than those who underwent autologous graft reconstruction, according to researchers from the U.S. Military Academy at West Point, NY.
ABERDEEN PROVING GROUND, MD - A new study is the first to identify injury rates and identify specific factors increasing injury risk during military police (MP) training in the Army.
RICHMOND, VA - While knee-replacement surgery often is sought so patients can return to a more active lifestyle, patients who undergo the procedure might be at greater risk of gaining weight than those who have not had the surgery.
Immunization Now Covered for Men Up to Age 27
FALLS CHURCH, VA - In the year since TRICARE added coverage for the human papillomavirus (HPV) vaccine in all males up to age 27, the challenge has been both educating military personnel and their families about the need for the shots and assuring that the recommended three doses are received.
WAYNE, NJ - Tthe U.S. Food and Drug Administration (FDA) has approved Bayer's Stivarga (regorafenib) tablets to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate, according to Bayer HealthCare and Onyx Pharmaceuticals, Inc.
SAN FRANCISCO - The FDA has approved Kadcyla (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy.
TEMPLE, TX - Retired Brig. Gen. James T. Turlington, MD, may no longer be an active duty general officer in the Air Force, but he’s still practicing medicine — and still making a difference.
Most Popular Stories
- Many Healthcare Providers Lose VA Retention Bonuses
- Federal Medicine Organizational Meetings — Tarred with the Same Brush?
- Despite Formulary, High-Cost Diabetes Drug Use Varies Widely Across VA Facilities
- Report Says Administration Faces Hard Choices For Veterans Programs
- Physician Overcomes TBI to Return to Active-Duty Medicine
Join Our E-Mail List